DAFNA Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

DAFNA Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-430,291	Closed	-$779K	–	81
2023 Q2	$779K	Sell	430,291 -49,095	-10%	-$89.8K	0.21%	56
2023 Q1	$633K	Hold	479,386	–	–	0.19%	58
2022 Q4	$810K	Hold	479,386	–	–	0.23%	56
2022 Q3	$887K	Buy	479,386 +28,281	+6%	+$84.3K	0.24%	62
2022 Q2	$1.39M	Buy	451,105 +29,948	+7%	+$183K	0.38%	54
2022 Q1	$3.04M	Buy	421,157 +187,657	+80%	+$1.85M	0.79%	35
2021 Q4	$3.82M	Sell	233,500 -66,450	-22%	-$773K	0.96%	30
2021 Q3	$2.98M	Sell	299,950 -50	-0%	-$497	0.79%	30
2021 Q2	$2.99M	Hold	300,000	–	–	0.63%	39
2021 Q1	$2.99M	Buy	+300,000	New	+$3.1M	0.71%	36

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

DAFNA Capital Management's PRDS Position: Q3 2023 in Review

DAFNA Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 430,291 shares — an estimated $779K sold.

DAFNA Capital Management first reported a position in PRDS in Q1 2021 and held it in 10 quarters. The position peaked at $3.82M in Q4 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

DAFNA Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
DAFNA Capital Management sold 430,291 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $779K.
DAFNA Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
DAFNA Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $3.82M in Q4 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.